Promising disease modifying approach to Duchenne muscular dystrophy with NeuREFIX Beta 1316 glucan from Japan the first such clinical report.

Duchenne Muscular Dystrophy DMD patients showed signs of disease progress slowing down after oral consumption of Neu REFIX glucan for 45 days along with routine medications.

Related Keywords

Tokyo ,Japan ,United States ,Japanese ,Aureobasidium Pullulans ,Samuel Jk Abraham ,Naoki Yamamoto ,International Holding Group ,Muscular Dystrophy ,Business Wire ,Holding Group ,Limb Girdle Muscle Dystrophy ,Media Contact ,